Money Matters - Simplified

CEL-SCI

CEL-SCI Investors Cheer a Bit Too Loudly


I don't usually write about the starts of clinical trials, and I've even been known to send snarky replies to PR people who pitch them to me via email. I mean, really, tell me when the thing ends; that's the data investors care about, since it drives the stock price.